Clinical Scorecard: Infections and Hypogammaglobulinemia Among Myasthenia Gravis Patients on Long-Term Low-Dose Rituximab: Findings from a Retrospective Cohort Analysis
At a Glance
Category
Detail
Condition
Myasthenia Gravis
Key Mechanisms
Autoantibodies against neuromuscular junction components impair neuromuscular transmission.
Target Population
Patients with Myasthenia Gravis undergoing long-term low-dose rituximab maintenance.
Care Setting
Neurology department in a tertiary medical center.
Key Highlights
Infection incidence was 15.59% among patients on low-dose rituximab.
Lower respiratory tract infections were the most common, accounting for 61.29% of infections.
Hypogammaglobulinemia was found in 27.42% of patients and was a significant predictor of infection.
Higher baseline prednisone doses correlated with increased risk of severe lower respiratory tract infections.
Guideline-Based Recommendations
Diagnosis
Monitor for infections in patients receiving long-term rituximab.
Management
Consider the risk of hypogammaglobulinemia when treating with rituximab.
Monitoring & Follow-up
Regular follow-up evaluations post-infusion to assess for infections and hypogammaglobulinemia.
Risks
Increased risk of infections, particularly severe lower respiratory tract infections, associated with hypogammaglobulinemia and higher prednisone doses.
Patient & Prescribing Data
186 Myasthenia Gravis patients treated with low-dose rituximab.
Long-term low-dose rituximab is associated with a relatively low incidence of infections.
Clinical Best Practices
Implement infection prevention strategies for patients on rituximab.
Evaluate baseline immunoglobulin levels before initiating rituximab therapy.
